Alpine Immune Sciences, Inc. Common Stock

During the last three months, 11 analysts shared their evaluations of Alpine Immune Sciences (NASDAQ:ALPN), revealing diverse outlooks from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 4 4 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 3 3 3 0 0 3M Ago 0 1 0 0 0 Analysts have recently evaluated Alpine Immune Sciences and provided 12-month price targets. The average target is $54.0, accompanied by a high estimate of $65.00 and a low estimate of $41.00. Surpassing the previous average price target of $38.00, the current average has increased by 42.11%. Deciphering Analyst Ratings: An In-Depth Analysis An in-depth analysis of recent analyst actions unveils how financial experts perceive Alpine Immune Sciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Robert Driscoll Wedbush Maintains Neutral $65.00 - Thomas Smith Leerink Partners Raises Market Perform $65.00 $42.00 Gregory Renza RBC Capital Raises Sector Perform $65.00 $41.00 Michael Ulz Morgan Stanley Raises Equal-Weight $65.00 $47.00 Vamil Divan Guggenheim Announces Buy $55.00 - Joseph Pantginis HC Wainwright & Co. Maintains Buy $50.00 $50.00 Michael Ulz Morgan Stanley Raises Overweight $47.00 $30.00 Robert Driscoll Wedbush Maintains Outperform $47.00 - Matthew Biegler Oppenheimer Raises Outperform $44.00 $33.00 Joseph Pantginis HC Wainwright & Co. Raises Buy $50.00 $32.00 Gregory Renza RBC Capital Raises Outperform $41.00 $29.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Alpine Immune Sciences. This information provides ...Full story available on Benzinga.com

Related tickers: ALPN.

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of 18.37% and 2.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Related tickers: ZVRA, ALPN.